Skip to content
Calculator
Evidence: LowPeptideDiscontinuedAngiotensin-(1-7) analoguePhase 3 for diabetic foot ulcersNot approved

Aclerastide

A small angiotensin peptide, made sturdier, applied as a gel to speed the healing of diabetic foot ulcers; it reached phase 3, where its trials were stopped

The renin-angiotensin system is best known for controlling blood pressure, but one of its arms, built around the peptide angiotensin-(1-7) and the Mas receptor, instead promotes repair: it encourages new blood vessels, cell growth and tissue remodelling. Aclerastide, coded DSC-127, is angiotensin-(1-7) with one amino acid swapped to make it last longer. Developed as a topical gel, it was tested to speed the healing of diabetic foot ulcers, wounds that are slow to close and a major cause of amputation. A phase 2 trial found it accelerated healing, but its phase 3 programme was terminated and it was not approved; it is not a marketed medicine.

Used in human trials: 0.01–0.03 %, once daily, topical (Studied dose) Details ↓

Overview

What is it?

A diabetic foot ulcer is a wound that will not close. High blood sugar damages nerves and small blood vessels, so the foot loses sensation and its blood supply, and an ordinary graze can become a chronic, colonised sore that risks bone infection and amputation. Standard care is pressure relief, wound care and control of blood sugar; drugs that actively speed healing are few, and the main one, a growth-factor gel, has limited benefit. Aclerastide was aimed at that gap.

It comes from an unexpected part of the renin-angiotensin system. Alongside the familiar arm that raises blood pressure (angiotensin II acting on the AT1 receptor) sits a counter-arm: the enzyme ACE2 makes angiotensin-(1-7), which acts on the Mas receptor to promote the growth of new blood vessels, the multiplication of skin and repair cells, and orderly tissue rebuilding. Those are exactly the steps a stalled wound needs. The drawback is that angiotensin-(1-7), like most peptides, is broken down quickly.

Aclerastide is angiotensin-(1-7) with its position-three amino acid replaced by norleucine, which makes it more stable while keeping the repair-promoting action, hence its research name NorLeu3-A(1-7). In animals it accelerated the healing of normal and diabetic wounds, reduced scarring after deep cuts, and sped the closure of corneal wounds, applied topically in each case.

The key human test was a phase 2 trial. In 172 people with chronic diabetic foot ulcers, four weeks of a once-daily gel at 0.03 percent or 0.01 percent, followed by standard care, shrank the ulcers more than placebo in a clear dose-dependent way: by 24 weeks the ulcers had closed in a median of 8.5 weeks on the stronger gel against 22 weeks on placebo. The drug was reported safe, and the result was called preliminary evidence of benefit.

On that strength it went to phase 3, the largest and final stage of testing, with three diabetic-foot-ulcer trials. All three were terminated, and the drug was not approved. The published record ends with the mechanism and the phase 2 promise rather than a confirmed clinical benefit. Aclerastide is an investigational compound, is not a medicine, and nothing here is a dose to use; a diabetic foot ulcer is a serious wound that needs proper medical care.

8.5 vs 22 wk
Median time for ulcers to heal
0.03% gel vs placebo, phase 2 · PMID 22672145
Phase 3
Highest stage reached
Three phase 3 trials terminated; approved nowhere · ChEMBL CHEMBL4297940
Structured data

At a Glance

Every value in this table is printed from the Grey Peptides dataset, the same record the compound explorer and comparison tool read, so the three can never disagree.

ClassA stabilised heptapeptide analogue of the repair peptide angiotensin-(1-7), developed as a topical gel to speed the healing of diabetic foot ulcers; it reached phase 3, where its trials were terminated.
SequenceAsp-Arg-Nle-Tyr-Ile-His-Pro, a heptapeptide analogue of angiotensin-(1-7) with norleucine at position 3 (FDA GSRS UNII YYD6UT8T47)
Half-lifelonger-acting than angiotensin-(1-7); applied topically once daily
Studied dose0.01–0.03 % (once daily, topical)
US statusDiscontinued
Evidence levelLow
Last reviewed2026-11-05
Science

Mechanism of Action

Aclerastide works through the repair arm of the renin-angiotensin system. It is a longer-lasting copy of angiotensin-(1-7), activating the Mas receptor to drive the steps a stalled wound needs.

🩹

Mas receptor and tissue repair

Angiotensin-(1-7), and aclerastide as its stable analogue, act on the Mas receptor, the counter-regulatory arm of the renin-angiotensin system, to promote cell proliferation, new blood-vessel growth and dermal repair (PMID 12621191) — the processes that close a wound.

🧬

Norleucine for stability

Replacing angiotensin-(1-7)'s position-3 residue with norleucine (FDA GSRS UNII YYD6UT8T47) slows the peptide's breakdown while keeping its repair action, which is what let it be applied as a topical gel (PMIDs 15953051, 22672145).

🩸

New vessels and remodelling

In animal wounds it accelerated healing and reduced scarring (PMIDs 21973177, 15953051), effects consistent with stimulating angiogenesis and orderly tissue remodelling rather than simply covering the wound.

Evidence

Published Research

These are studies of aclerastide read from their PubMed abstracts on November 5, 2026. The clinical record is a single phase 2 randomized trial in diabetic foot ulcers; the rest is animal work on wound and scar healing and on the cornea. One title names no drug and is carded because its abstract names it. Three phase 3 trials were later terminated (ClinicalTrials.gov).

Human2012

Phase 2 trial in diabetic foot ulcers

A randomized, double-blind, placebo-controlled phase 2 trial in 172 people with chronic neuropathic or neuroischaemic diabetic foot ulcers. Four weeks of once-daily topical gel at 0.03 percent (26 patients) or 0.01 percent (27 patients), or placebo (24), were followed by 20 weeks of standard care. The reduction in ulcer area at weeks 12 and 24 rose with dose, and ulcers closed in a median of 8.5 weeks on the 0.03 percent gel against 22 weeks on placebo (p=0.04). The drug was reported safe. The authors called it preliminary evidence that the gel accelerates diabetic-foot-ulcer healing.

PMID: 22672145
Animal2011

Diabetic wound healing

A study of NorLeu3-angiotensin-(1-7) in diabetic wound models. Diabetes delays repair and leaves chronic wounds; the peptide accelerated the healing of diabetic wounds, supporting the move into clinical testing for diabetic foot ulcers, where the only approved active product (a growth-factor gel) has limited effect.

PMID: 21973177
Animal2005

Scar formation after a deep cut

In rats, NorLeu3-A(1-7) was applied to full-thickness incision wounds and scar formation was followed over time. The peptide accelerated dermal healing and reduced the fibrotic scar, pointing to a role not just in closing wounds but in how neatly they heal.

PMID: 15953051
Animal2016

Corneal wound healing

NorLeu3-angiotensin-(1-7), formulated for the eye, accelerated the healing of full-thickness clear-corneal wounds. It extended the peptide's wound-repair action from skin to the transparent surface of the eye, where fast, clear healing matters for vision.

PMID: 27116546
Animal2003

Three wound-healing models

The first report of NorLeu3-angiotensin-(1-7) in wound healing. Angiotensin peptides were known to influence cell growth, new blood-vessel formation and dermal repair; here the analogue was tested across three models of epithelial wound healing, including normal and impaired repair, and accelerated healing while normalising tissue architecture.

PMID: 12621191
Safety

Side Effects & Contraindications

Reported Side Effects

From the phase 2 trial; there is no approved-label safety profile.

● Reported safe in the phase 2 diabetic-foot-ulcer trial, applied topically once daily (PMID 22672145)
● As a topical gel its exposure is local, limiting the usual concerns of a blood-pressure-system peptide
● No long-term or large-scale human safety data are published, as the phase 3 trials were terminated

Contraindications & Cautions

Aclerastide has no label and no approved use. These points come from the trials and the molecule.

● Not an available medicine: approved nowhere, and the phase 3 programme was terminated
● A diabetic foot ulcer is a serious wound needing proper wound care, infection control and blood-sugar management; no gel replaces that
● No human interaction, pregnancy or long-term data exist for aclerastide
● It is investigational and was studied only as a prescription gel under trial conditions
Questions

Frequently Asked Questions

?What is aclerastide?

An experimental wound-healing drug, coded DSC-127, that is a stabilised copy of the body's repair peptide angiotensin-(1-7). Applied as a gel, it was developed to speed the healing of diabetic foot ulcers.

?Did it work?

In a phase 2 trial of 172 people, the 0.03 percent gel closed diabetic foot ulcers faster than placebo (median 8.5 vs 22 weeks) and was reported safe (PMID 22672145). But its three phase 3 trials were terminated and it was not approved, so the benefit was never confirmed at the final stage.

?How does it differ from blood-pressure drugs?

It works through the opposite, repair-promoting arm of the same system. Blood-pressure drugs block angiotensin II and the AT1 receptor; aclerastide mimics angiotensin-(1-7) and activates the Mas receptor, which encourages healing rather than raising pressure.

?Is it approved?

No. There is no FDA application or label as of November 5, 2026, and no approval elsewhere. Its phase 3 programme was terminated.

?Is it available to buy?

No. Aclerastide is not a medicine and is not sold as one. Grey Peptides lists no sellers and recommends no source; this page records the published science.

Bibliography

References

  1. [clinical-trial] Balingit PP, et al. "NorLeu3-A(1-7) stimulation of diabetic foot ulcer healing: results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial." Wound Repair Regen, 2012;20(4):482-90. PMID: 22672145.
  2. [animal] Rodgers K, et al. "Accelerated healing of diabetic wounds by NorLeu(3)-angiotensin (1-7)." Expert Opin Investig Drugs, 2011;20(11):1575-81. PMID: 21973177.
  3. [animal] Rodgers KE, et al. "Effect of NorLeu3-A(1-7) on scar formation over time after full-thickness incision injury in the rat." Wound Repair Regen, 2005;13(3):309-17. PMID: 15953051.
  4. [animal] Abdallah WF, et al. "NorLeu3A(1-7) Accelerates Clear Corneal Full Thickness Wound Healing." Invest Ophthalmol Vis Sci, 2016;57(4):2187-94. PMID: 27116546.
  5. [animal] Rodgers KE, et al. "Acceleration of healing, reduction of fibrotic scar, and normalization of tissue architecture by an angiotensin analogue, NorLeu3-A(1-7)." Plast Reconstr Surg, 2003;111(3):1195-206. PMID: 12621191.
  6. [other] FDA Global Substance Registration System, Aclerastide, UNII YYD6UT8T47 (INN 9877, CAS 227803-63-6, PubChem 9811551; code DSC-127), read November 5, 2026: a heptapeptide analogue of angiotensin-(1-7), L-aspartyl-L-arginyl-L-norleucyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-proline (angiotensin-(1-7) with norleucine at position 3). https://gsrs.ncats.nih.gov/ginas/app/beta/substances/YYD6UT8T47
  7. [other] ChEMBL molecule CHEMBL4297940 (ACLERASTIDE), read November 5, 2026: synonyms Aclerastide, Aclerastida, DSC-127, Asp-Arg-Nle-Tyr-Ile-His-Pro; highest clinical phase recorded 3. https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297940/
  8. [other] US FDA, Drugs@FDA and the drug label endpoint (openFDA), searched November 5, 2026: no application and no label record for aclerastide. It has an FDA substance record (UNII YYD6UT8T47) and an INN.
  9. [registry] ClinicalTrials.gov API v2, searched November 5, 2026: five records for DSC-127 / aclerastide. NCT00796744 (phase 2 in diabetic foot ulcers, completed); NCT01830348, NCT01840085 and NCT01849965 (three phase 3 diabetic-foot-ulcer trials, all terminated); NCT03615196 (phase 1, completed). The phase 3 programme did not reach approval. https://clinicaltrials.gov/search?term=aclerastide

Sources & Citations

The five studies carded above were read from their PubMed records on November 5, 2026. Structure, codes and identifiers come from the FDA Global Substance Registration System (UNII YYD6UT8T47) and ChEMBL (CHEMBL4297940); the absence of approval from Drugs@FDA and openFDA, and the trial list and their terminated status from ClinicalTrials.gov, all checked the same day. Grey Peptides sells nothing and links to no vendor.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Consult a licensed healthcare provider before making health decisions.

Last reviewed: 2026-11-05